Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 25

Sort by

Sort Order Select

Journal Articles

Comparable Outcomes of Point-of-Care and Commercial CD19 CAR-T Therapies: A Patient-Matched Analysis in Large B-Cell Lymphoma

Blood (2024) 144 (Supplement 1): 608.

https://doi.org/10.1182/blood-2024-207638

Published: 2024

Journal Articles

The Ability of Currently Used Scoring Systems to Predict 30 and 100-Days Non-Relapse Mortality Among Older Adults Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

Amir Tafesh, Dana Yehudai-Ofir, Ofrat Beyar-Katz, Hazim Khatib, Baher Krayem, Avraham Frisch, Tsila Zuckerman, Israel Henig

Blood (2024) 144 (Supplement 1): 3482.

https://doi.org/10.1182/blood-2024-194308

Published: 2024

Journal Articles

Reduction in Platelet Counts May Predict the Development of Immune Effector Cell Associated Neurotoxicity Syndrome in Patients Receiving CD19 CAR-T Cell Therapy for Relapsed/Refractory Large B Cell Lymphoma

Blood (2024) 144 (Supplement 1): 1748.

https://doi.org/10.1182/blood-2024-202937

Published: 2024

Journal Articles

Belumosudil Is Efficacious for the Management of Heavily Pretreated and Prolonged Chronic Graft-Versus-Host Disease: A Retrospective Multi-Center Real-World Study By the Israel Association for Bone Marrow Transplantation and Cellular Therapy

Ben Varon, Ron Ram, Avichai Shimoni, Batia Avni, Sigal Grisariu, Vered Stavi, Yael Bar-On, Moshe Yeshurun, Ronit Elhasid, Aharon Gefen, Asaf Yanir, Odelia Amit, Dana Yehudai-Ofir, Israel Henig, Tsila Zuckerman

Blood (2024) 144 (Supplement 1): 7338.

https://doi.org/10.1182/blood-2024-206874

Published: 2024

Journal Articles

For Patients with Adverse-Risk Acute Myeloid Leukemia, Frontline FLAG Ida with Venetoclax Is Safe and Efficacious

Baher Krayem, Avraham Frisch, Tsila Zuckerman, Israel Henig, Dana Yehudai-Ofir, Boaz Nachmias, Hazim Khatib, Arnon Haran, Shlomzion Aumann

Blood (2024) 144 (Supplement 1): 4269.

https://doi.org/10.1182/blood-2024-204627

Published: 2024

Journal Articles

Safety and Preliminary GvHD Mitigation in First in Human Clinical Trial of Apograft in Match Related Stem Cell Transplantation (SCT)

Tsila Zuckerman, Polina Stepensky, Dana Yehudai-Ofir, Israel Henig, Moshe Kamar, Jerry Stein

Blood (2021) 138 (Supplement 1): 2893.

https://doi.org/10.1182/blood-2021-149419

Published: 2021

Journal Articles

Omitting Fluoroquinolones Antibiotic Prophylaxis in Allogeneic Hematopoietic Stem Cell Transplantation Does Not Increase Gram-Negative Bacteremia Rate or Transplant-Related Mortality

Israel Henig, MD, Oryan Henig, Haggai Bar-Yoseph, Hanin Daoud, Dana Yehudai-Ofir, MD, Ilana Oren, Tsila Zuckerman, MD

Blood (2020) 136 (Supplement 1): 34–35.

https://doi.org/10.1182/blood-2020-142357

Published: 2020

Journal Articles

NPM1 Quantitative Monitoring of Minimal Residual Disease in Acute Myeloid Leukemia Allows More Precise Selection of Patients for Allogeneic Stem Cell Transplantation without Affecting Their Survival

Yishai Ofran, MD, Ronit Leiba, Dina Rosenberg, Israel Henig, MD, Dana Yehudai-Ofir, MD, Nuhad Haddad, MD, Riva Fineman, MD, Avraham Frisch, MD, Doaa Okasha, MD, Yariv Carasso, MD, Tsila Zuckerman, MD, Nurit Horesh, MD

Blood (2019) 134 (Supplement_1): 2603.

https://doi.org/10.1182/blood-2019-126553

Published: 2019

Journal Articles

Radiation-Free Protocol for Patients with Acute Lymphoblastic Leukemia and Mixed Phenotype Acute Leukemia Undergoing Induction Chemotherapy and Allogeneic Hematopoietic Cell Transplantation - a Multicenter Historical Prospective Study

Odelia Amit, MD, Yael Bar-On, MD, Irit Avivi, Tsila Zuckerman, MD, Galit Perets, MD, Israel Henig, MD, Itai Levi, MD, Dana Yehudai-Ofir, MD, Shimrit Ringelstein Harlev, MD, Ron Ram, MD

Blood (2019) 134 (Supplement_1): 5654.

https://doi.org/10.1182/blood-2019-128248

Published: 2019

Journal Articles

Donor T Cell Independent Mechanism Is Critical for Mediating Steroid Refractory Gvhd in Murine Models

Tomomi Toubai, MDPhD, Corrine Rossi, Isao Tawara, MD PhD, Chen Liu, MD PhD, Cynthia Zajac, Katherine Oravecz-Wilson, BS, MS, Dan Peltier, MD, Yaping Sun, MD PhD MS, Hideaki Fujiwara, MD, Mary Mansour Riwes, DO, Israel Henig, MD, Stephanie Kim, BS, Masahiro Suto, Kenichi Ishizawa, MD PhD, Pavan Reddy, MD

Blood (2018) 132 (Supplement 1): 4529.

https://doi.org/10.1182/blood-2018-99-114634

Published: 2018

Journal Articles

Targeting Sec23b in COPII Vesicles Regulates T Cell Immunity

Stephanie Kim, BS, Rami Khoriaty, MD, Rajesh Valanparambil, PhD, Julia Wu, PhD, Austin Taylor, BS, Hideaki Fujiwara, MD, Dan Peltier, MD, Yaping Sun, MD PhD MS, Israel Henig, MD, Cynthia Zajac, Katherine Oravecz-Wilson, BS, MS, Stuart Brabbs, Rafi Ahmed, PhD, David Ginsburg, MD, Pavan Reddy, MD

Blood (2018) 132 (Supplement 1): 859.

https://doi.org/10.1182/blood-2018-99-111628

Published: 2018

Journal Articles

Metabolic Reprogramming of Dendritic Cells Is Controlled By the Mir-142

Yaping Sun, MD PhD MS, Thomas Saunders, PhD, Katherine Oravecz-Wilson, BS, MS, Sydney Bridges, BS, Richard McEachin, PhD, Julia Wu, PhD, Stephanie Kim, Cynthia Zajac, Tomomi Toubai, MDPhD, Hideaki Fujiwara, Israel Henig, MD, Dan Peltier, MD, Pavan Reddy, MD

Blood (2017) 130 (Supplement 1): 2265.

https://doi.org/10.1182/blood.V130.Suppl_1.2265.2265

Published: 2017

Journal Articles

BST-236, a Novel Cytarabine Pro-Drug, Enables Safe and Effective Administration of High Dose Cytarabine to Older or Unfit Patients with Acute Leukemia. Results of a Phase I/II Study

Tsila Zuckerman, MD, Ron Ram, MD, Maya Koren-Michowitz, MD, Luiza Akria, MD, Ron Hoffman, Israel Henig, MD, Yishai Ofran, MD, Noa Lavi, MD, Netanel A Horowitz, MD, Olga Nudelman, MD, Shay Yeganeh, MD, Stela Gengrinovitch, PhD, Liat Flaishon, PhD MD, Ruth Ben Yakar, PhD, Jacob M. Rowe, MD

Blood (2017) 130 (Supplement 1): 893.

https://doi.org/10.1182/blood.V130.Suppl_1.893.893

Published: 2017

Journal Articles

Vorinostat plus tacrolimus/methotrexate to prevent GVHD after myeloablative conditioning, unrelated donor HCT

Sung Won Choi, Thomas Braun, Israel Henig, Erin Gatza, John Magenau, Brian Parkin, Attaphol Pawarode, Mary Riwes, Greg Yanik, Charles A. Dinarello, Pavan Reddy

Blood (2017) 130 (15): 1760–1767.

https://doi.org/10.1182/blood-2017-06-790469

Published: 2017

Journal Articles

Astarabine, a Novel Leukemia-Targeted Cytarabine Composition Allows, for the First Time, the Delivery of High Cytarabine Doses for Older or Unfit Patients with Acute Leukemia. Results of an Ongoing Phase I/IIa Study

Tsila Zuckerman, MD, Stela Gengrinovitch, PhD, Ruth Ben-Yakar, PhD, Ron Hoffman, MD, Israel Henig, MD, Noa Lavi, MD, Luiza Akria, MD, Yishai Ofran, MD, Netanel A Horowitz, MD, Olga Nudelman, MD, Maya Koren-Michowitz, MD, Shay Yeganeh, MD, Martin S. Tallman, MD, Jacob M. Rowe, MD

Blood (2016) 128 (22): 1650.

https://doi.org/10.1182/blood.V128.22.1650.1650

Published: 2016

Journal Articles

Autologous Stem Cell Transplantation in Favorable Acute Myeloid Leukemia Is Associated with a Better Long-Term Prognosis: a Single Center Experience

Ofrat Beyar-Katz, MD, Israel Henig, MD, Dana Yehudai, MD, Nov Yuval, MSc, Riva Fineman, MD, Nuhad Haddad, MD, Yishai Ofran, MD, Jacob M. Rowe, MD, Tsila Zuckerman, MD

Blood (2016) 128 (22): 5819.

https://doi.org/10.1182/blood.V128.22.5819.5819

Published: 2016

Journal Articles

Astarabine, a Pro-Drug of Cytarabine, Is Safe for Patients with Advanced Acute Leukemia. A Phase I/IIa Single Center Study in Relapsed/Refractory or Medically Unfit Patients

Tsila Zuckerman, MD, Ruth Ben Yakar, PhD, Stela Gengrinovitch, PhD, Ron Hoffman, MD, Israel Henig, MD, Noa Lavi, MD, Luiza Akria, MD, Yishai Ofran, MD, Olga Nudelman, MD, Nuhad Haddad, MD, Martin S Tallman, MD, Jacob M. Rowe, MD

Blood (2015) 126 (23): 3810.

https://doi.org/10.1182/blood.V126.23.3810.3810

Published: 2015

Journal Articles

Semaphorin 3A Expression on Donor and Recipient Regulatory Cells: A Novel Pre-Transplant Biomarker Predicting the Development of Acute Graft-Versus-Host Disease

Zahava Vadas, MD PhD, Eti Ganon-Elazar, PhD, Yuval Nov, PhD, Israel Henig, MD, Dina Attias, MD, Nuhad Haddad, MD, Riva Fineman, MD, Jacob M. Rowe, MD, Tsila Zuckerman, MD

Blood (2014) 124 (21): 3935.

https://doi.org/10.1182/blood.V124.21.3935.3935

Published: 2014

Journal Articles

Efficacy and Safety of Autologus Hematopoietic Cell Transplantation in Elderly Patients with Multiple Myeloma: A Retrospective Israeli Multi-Site Cohort Study

Yael C Cohen, MD, Tsila Zuckerman, MD, Moshe Yeshurun, MD, Galit Perez, MD, Hila Magen, MD, Israel Henig, MD, Itai Levi, MD, Liat Shargian, Svetlana Trestman, MD, Uri Rouvio, MD, Elizabeth Naparstek, MD, Eti Ganon-Elazar, PhD, Irit Avivi, MD, Ron Ram, MD

Blood (2014) 124 (21): 3989.

https://doi.org/10.1182/blood.V124.21.3989.3989

Published: 2014

Journal Articles

Stable Blood Group Chimerism in Recipients of ABO Incompatible Allogeneic Stem Cell Transplantation

Ami Glik, MD, Lilach Bonstein, PhD, Nardeen Atwah, BSc, Eti Ganon-Elazar, PhD, Israel Henig, MD, Nuhad Haddad, MD, Riva Fineman, MD, Jacob M. Rowe, MD, Tsila Zuckerman, MD

Blood (2014) 124 (21): 1553.

https://doi.org/10.1182/blood.V124.21.1553.1553

Published: 2014

NARROW

Comparable Outcomes of Point-of-Care and Commercial CD19 CAR-T Therapies: A Patient-Matched Analysis in Large B-Cell Lymphoma

The Ability of Currently Used Scoring Systems to Predict 30 and 100-Days Non-Relapse Mortality Among Older Adults Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

Reduction in Platelet Counts May Predict the Development of Immune Effector Cell Associated Neurotoxicity Syndrome in Patients Receiving CD19 CAR-T Cell Therapy for Relapsed/Refractory Large B Cell Lymphoma

Belumosudil Is Efficacious for the Management of Heavily Pretreated and Prolonged Chronic Graft-Versus-Host Disease: A Retrospective Multi-Center Real-World Study By the Israel Association for Bone Marrow Transplantation and Cellular Therapy

For Patients with Adverse-Risk Acute Myeloid Leukemia, Frontline FLAG Ida with Venetoclax Is Safe and Efficacious

Safety and Preliminary GvHD Mitigation in First in Human Clinical Trial of Apograft in Match Related Stem Cell Transplantation (SCT)

Omitting Fluoroquinolones Antibiotic Prophylaxis in Allogeneic Hematopoietic Stem Cell Transplantation Does Not Increase Gram-Negative Bacteremia Rate or Transplant-Related Mortality

NPM1 Quantitative Monitoring of Minimal Residual Disease in Acute Myeloid Leukemia Allows More Precise Selection of Patients for Allogeneic Stem Cell Transplantation without Affecting Their Survival

Radiation-Free Protocol for Patients with Acute Lymphoblastic Leukemia and Mixed Phenotype Acute Leukemia Undergoing Induction Chemotherapy and Allogeneic Hematopoietic Cell Transplantation - a Multicenter Historical Prospective Study

Donor T Cell Independent Mechanism Is Critical for Mediating Steroid Refractory Gvhd in Murine Models

Targeting Sec23b in COPII Vesicles Regulates T Cell Immunity

Metabolic Reprogramming of Dendritic Cells Is Controlled By the Mir-142

BST-236, a Novel Cytarabine Pro-Drug, Enables Safe and Effective Administration of High Dose Cytarabine to Older or Unfit Patients with Acute Leukemia. Results of a Phase I/II Study

Vorinostat plus tacrolimus/methotrexate to prevent GVHD after myeloablative conditioning, unrelated donor HCT

Astarabine, a Novel Leukemia-Targeted Cytarabine Composition Allows, for the First Time, the Delivery of High Cytarabine Doses for Older or Unfit Patients with Acute Leukemia. Results of an Ongoing Phase I/IIa Study

Autologous Stem Cell Transplantation in Favorable Acute Myeloid Leukemia Is Associated with a Better Long-Term Prognosis: a Single Center Experience

Astarabine, a Pro-Drug of Cytarabine, Is Safe for Patients with Advanced Acute Leukemia. A Phase I/IIa Single Center Study in Relapsed/Refractory or Medically Unfit Patients

Semaphorin 3A Expression on Donor and Recipient Regulatory Cells: A Novel Pre-Transplant Biomarker Predicting the Development of Acute Graft-Versus-Host Disease

Efficacy and Safety of Autologus Hematopoietic Cell Transplantation in Elderly Patients with Multiple Myeloma: A Retrospective Israeli Multi-Site Cohort Study

Stable Blood Group Chimerism in Recipients of ABO Incompatible Allogeneic Stem Cell Transplantation

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only